PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 127.11% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2026-03-20
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2023-03-31 was 69.54%, a 5.73% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2022-03-31 was 73.77%.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2025 was 127.11%, a 13.76% increase from fiscal 2024.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2024 was 111.74%, a 42.62% increase from fiscal 2023.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2023 was 78.35%, a 6.37% increase from fiscal 2022.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2022 was 73.66%, a 0.89% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 127.11% 10-K · filed 2026-03-20 | |||
| 2024-12-31 | 111.74% 10-K · filed 2026-03-20 | |||
| 2023-12-31 | 78.35% 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 68.75% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 68.75% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 69.54% 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 73.66% 10-K · filed 2024-03-26 | |||
| 2022-09-30 | 73.66% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 73.70% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 73.77% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 74.32% 10-K · filed 2023-03-22 | |||
| 2021-09-30 | 76.05% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 76.05% 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | 80.00% 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |